Vasoactive intestinal peptide degradation might influence Interleukin-17 expression in cardiac chagasic patients by Pereira, Francielle Beltrão et al.
Rev Inst Med Trop São Paulo. 2018;60:e57 Page 1 of 10
ORIGINAL ARTICLE
http://dx.doi.org/10.1590/S1678-9946201860057
1Universidade Federal de Minas Gerais, 
Faculdade de Farmácia, Departamento 
de Análises Clínicas e Toxicológicas, Belo 
Horizonte, Minas Gerais, Brazil
2Universidade Federal de Minas 
Gerais, Instituto de Ciências Biológicas, 
Departamento de Morfologia, Belo 
Horizonte, Minas Gerais, Brazil
3Instituto Nacional de Ciência e Tecnologia 
de Doenças Tropicais, Salvador, Bahia, 
Brazil
4A.C. Camargo Cancer Center, Centro 
Internacional de Pesquisa, São Paulo, São 
Paulo, Brazil
5Universidade Federal de Minas Gerais, 
Instituto de Ciências Exatas, Departamento 
de Estatística, Belo Horizonte, Minas 
Gerais, Brazil
6Universidade Federal de Minas Gerais, 
Faculdade de Medicina, Programa de 
Pós-Graduação em Doenças Infecciosas 
e Medicina Tropical, Belo Horizonte, Minas 
Gerais, Brazil.
Correspondence to: Cristiane Alves da 
Silva Menezes 
Universidade Federal de Minas Gerais, 
Faculdade de Farmácia, Departamento de 
Análises Clínicas e Toxicológicas, Avenida 
Presidente Antônio Carlos, 6627, CEP 
31270-901, Belo Horizonte, MG, Brazil 
Tel: +55 31 3409-6874 
Fax: + 55 31 3409-6985
E-mail: menezescristiane1@gmail.com
Received: 11 May 2018
Accepted: 14 August 2018
Vasoactive intestinal peptide degradation might influence 
Interleukin-17 expression in cardiac chagasic patients
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ABSTRACT
The vasoactive intestinal peptide (VIP) expression is lower in cardiac chagasic patients 
and is related to worse cardiac function. The reduction of VIP in patients with Chagas 
disease may be a result of its enhanced degradation. To test this hypothesis, the tryptase 
and chymase expression was evaluated. We also related VIP levels with interleukin-17 (IL-
17) expression since VIP may modulate IL-17 production. Plasma levels of chymase were 
higher in chagasic patients. Conversely, VIP/chymase and VIP/tryptase ratios were lower 
in chagasic patients when compared to non-infected individuals. Besides, the VIP/chymase 
ratio was lower in chagasic cardiac patients in comparison with the indeterminate group. A 
positive correlation between tryptase and chymase levels was observed in chagasic cardiac 
patients. In relation to IL-17, we observed a higher expression of this cytokine in the cardiac 
form of the disease than in the indeterminate form. IL-17/VIP ratio was higher in the cardiac 
form in comparison with non-infected or indeterminate form. These results suggest that the 
low levels of VIP observed in chagasic patients could be due to an increased production of 
chymase and/or to the additive effect of the interaction between chymase and tryptase in 
the cardiac form. Moreover, the decreased VIP expression may contribute to the increase of 
IL-17 in chagasic cardiac patients. 
KEYWORDS: Chagas disease. Tryptase. Chymase. Vasoactive intestinal peptide (VIP). 
Interleukin-17. IL-17.
INTRODUCTION
Chagas disease is a protozoonosis caused by Trypanosoma cruzi. In endemic 
areas, the disease is transmitted mostly by contact with contaminated feces of 
Triatominae bugs. Disease can also be transmitted by blood transfusion, organ 
transplantation, ingestion of contaminated food and via the congenital pathway1,2. 
Nowadays, it is estimated that about 7 million people worldwide, mostly in Latin 
America, are infected with T. cruzi3. Updated data from the American Community 
Survey and The World Health Organization estimated 238,000 cases across the United 
States4 and in some countries in Europe as a consequence of the migratory flows 
of asymptomatic infected individuals from Latin America5. Remarkably, in Latin 
America, this parasitic disease is one of the most important of the neglected ones 
affecting around 13% of the population, remaining a major public health problem 
causing incapacity in infected individuals and more than 10,000 deaths per year3.
Once infected, the individual will develop two distinct phases: acute and chronic. 
During the first, trypomastigote forms of T. cruzi are abundant in the bloodstream. 
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Approximately 2 months after infection, untreated/uncured 
individuals will develop the chronic phase of the disease, 
characterized by low parasitemia/low concentrations of the 
parasite in peripheral blood3. 
The chronic phase presents distinct clinical forms. 
There is an asymptomatic form, called indeterminate and 
symptomatic forms: cardiac, digestive and cardiodigestive. 
The symptomatic forms of Chagas disease progress from the 
indeterminate status to the clinical cardiac disease and/or 
gastrointestinal disease. The transition from the acute phase 
until reaching the symptomatic forms occurs within 10 
to 20 years, progressively6. There are many speculations 
about the factors involved in Chagas disease progression 
and a great interest in finding biomarkers to evidence the 
transition between asymptomatic to symptomatic forms.
The most significant clinical sequel of T. cruzi infection 
is chagasic cardiomyopathy. Around 20% to 30% of 
infected individuals will develop the cardiac clinical form, 
at variable time intervals after infection6. Reasons leading 
to the establishment of different clinical forms depend on 
complex interactions between the parasite and the hosts’ 
immune system7. An uncontrolled inflammatory response 
can lead to the cardiac form of Chagas disease and a 
controlled one favors the maintenance of the indeterminate 
form of the disease. 
Modulatory factors such as anti-inflammatory 
cytokines, glucocorticoids and neuropeptides are 
essential in controlling the inflammatory response. VIP 
is a neuropeptide produced by nervous and immune 
cells, which exerts a modulatory role over the immune 
response and may also act as a potent anti-trypanosome 
agent. Its trypanolytic activity was tested on Trypanosoma 
brucei and the disruption of the parasite was reached 
through a mechanism that involves peptides uptake by the 
parasite, disruption of lysosome integrity and cytosolic 
accumulation of glycolytic enzymes, which promotes an 
energetic metabolism failure that initiates an autophagic-
like cell death8. Modified VIP analogues, more stable than 
the native peptide, were able to kill various non-pathogenic 
and pathogenic Gram-positive and Gram-negative 
bacteria, as well as the parasite Leishmania major through 
a mechanism that depends on the interaction with certain 
components of the microbial surface, the formation of 
pores and the disruption of the surface membrane9.
On the other hand, VIP exerts its anti-inflammatory 
function through its receptors, VPAC1, VPAC2 and PAC1, 
which are expressed by several immune cells10. VIP acts 
inhibiting the production of inflammatory mediators and 
stimulating the production of anti-inflammatory cytokines 
by macrophages and microglia. Additionally, VIP decreases 
costimulatory molecule expression in macrophages and 
mature dendritic cells, which will affect T cells stimulation. 
VIP also modulates T lymphocyte response by inhibiting 
the Th1 cell differentiation, favoring the expansion of Th2 
cells and inducing the emergence of Treg cells (iTreg)11. 
Previous studies showed that VIP is able to exert an 
immunomodulatory function on Th17 subpopulation, 
which has been appointed as pathogenic cells in several 
autoimmune diseases12,13. In the context of Chagas disease, 
Magalhães et al.14, correlating IL-17 expressing cells 
and cardiac function in chagasic patients, demonstrated 
that chagasic cardiac patients presented a lower intensity 
of expression of IL-17 by total lymphocytes and that 
a higher cellular expression of IL-17 was associated 
with better cardiac function. Similarly, another study 
suggests a relationship between high plasma expression 
of IL-17A and a better cardiac function in chronic human 
Chagas disease15. However, studies relating IL-17 and 
the best prognosis in Chagas disease fail in explaining 
the mechanism by which this cytokine would improve 
cardiac function. 
It has been suggested that a reduction in VIP levels 
can contribute to the maintenance of inflammation in 
chronic diseases, which may lead to tissue damage16-19. 
We have previously shown that uninfected individuals and 
indeterminate Chagas patients presented a higher expression 
of VIP in their plasma when compared to cardiac Chagas 
patients, and that lower levels of VIP are associated with a 
worse ventricular function while higher levels of VIP are 
associated with better cardiac function. These data suggest 
a protective role to VIP in Chagas disease20.
It is possible to hypothesize that the decreased 
expression of VIP in cardiac patients could be related to 
a higher degradation rate of this neuropeptide. A classical 
work of Caughey et al.21, showed that mast cell proteases, 
tryptase and chymase, purified from dog mastocytomas are 
able to cleave VIP rapidly. Besides, chymase is also able to 
cleave another neuropeptide, named substance P. 
The aim of this work is to measure the expression of 
chymase and tryptase in indeterminate and chagasic cardiac 
patients, and evaluate the relationship between VIP and 
IL-17 expression in those patients to verify if there is a 
correlation between the expression of these enzymes and 
IL-17/VIP levels and also with chagasic cardiomyopathy 
morbidity.
MATERIALS AND METHODS
Patients
This study was based on a cross-sectional design, 
employing samples from patients in endemic areas of 
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Minas Gerais State, Brazil. This is an observational study, 
using convenience samples from chagasic patients and 
healthy individuals. Patients are treated in the Reference 
and Training Center in Infectious-Parasitic diseases of the 
Universidade Federal de Minas Gerais (UFMG), under 
the clinical care of one of the team members (MOCR). 
All the individuals were followed up according to 
standardized institutional protocols to avoid inconsistencies 
in classification and treatment. 
Clinical classification was performed according to 
criteria described by Rocha et al.22. Clinical evaluation 
included physical examinations and exams such as: 
electrocardiogram, chest radiography and echocardiogram. 
Based on the results of these exams, patients were 
classified into two different clinical groups: indeterminate 
patients (I), asymptomatic individuals with no significant 
alterations in electrocardiography, chest radiography and 
echocardiogram; and cardiac patients (C), characterized by 
echocardiographic manifestations of a dilated left ventricle 
with impaired ventricular systolic function. We have also 
included a group of subjects without Chagas disease, called 
non-infected individuals (NI) who had negative results of 
the specific serological test for Chagas disease. The total 
of 51 biological samples included different forms of the 
disease: I = 18; C = 14 and NI = 19. The exclusion criteria 
were: presence of diabetes mellitus, arterial hypertension, 
renal insufficiency, thyroid dysfunction, chronic obstructive 
pulmonary disease, rheumatic heart diseases and any other 
infectious disease. 
Ethics
All the participants of this study provided written 
informed consent. The study protocol was approved 
by the Research Ethics Committee of UFMG (CAAE: 
18606013.7.0000.5149/COEP/UFMG–ETIC006/05) and 
observed the principles established in the 1975 Declaration 
of Helsinki revised in 198323.
Quantification of VIP, chymase (CMA) and tryptase 
(TPS) by ELISA 
Blood samples were collected from the three different 
groups: chagasic patients (I = 18, C = 14) and non-infected 
individuals (NI = 19). Samples were collected in EDTA 
tubes and centrifuged to recover plasma samples. VIP, CMA 
and TPS plasma levels were measured using specific ELISA 
kits (Uscn Life Science, Huston, TX). The manufacturer’s 
protocols were followed. Plates were read in a microplate 
spectrophotometer at 450 nm and results were analyzed 
based on standard curves.
Quantification of IL-17A
A cytometric bead array (CBA), a bead-based 
immunoassay capable of measuring human cytokines in 
serum, plasma and cell culture supernatant samples was 
used (Becton Dickinson Biosciences, San Jose, CA, USA) to 
quantify plasma IL-17A expression. The test was performed 
according to the manufacturer’s instructions. Data were 
acquired in a BD LSRFortessa flow cytometry system and 
analyses were performed using the BD FCAP Array v3.0 
software. Results were based on a standard concentration 
curve and expressed as picograms per milliliter (pg/mL). 
The detection limit to IL-17 was 18.9 pg/L and results 
below this detection limit were excluded.
Statistical analysis
Data were analyzed for normal distribution by the 
Shapiro-Wilk test. Nonparametric data were analyzed by the 
Kruskall-Wallis for comparisons among the three groups. The 
Mann-Whitney test was used for comparison of two groups. 
Correlation analyses were performed using the Spearman 
linear correlation coefficient and squares regression. Results 
were nominally significant at two-sided p<0.05. Statistical 
analysis of data was performed by using the GraphPad Prism 
statistical software (version 6; San Diego, CA).
RESULTS
VIP, chymase and tryptase plasma levels
VIP, chymase and tryptase plasma levels were evaluated 
in the groups I (n = 18), C (n = 14) and NI (n = 19). VIP 
plasma levels were significantly lower in cardiac patients 
(5.1±0.7 pg/mL), when compared to non-infected individuals 
(11.1±1pg/mL) and indeterminate patients (8.2±0.9 pg/mL) 
(Figure 1A). In relation to chymase plasma levels, it was 
observed that chagasic patients from groups I (15.6 ng/mL) 
and C (24.81 ng/mL) forms presented a median of chymase 
3-4 times higher when compared to the NI group (6.8 ng/
mL; p<0.001 for both comparisons) (Figure 1A). There was 
no difference in the median of plasma chymase expression 
between chagasic patients of the two different clinical forms 
(Figure 1A). The median of tryptase plasma levels was not 
statistically different between the groups NI (31.2 ng/mL), I 
(42.32 ng/mL) and C (32.59 ng/mL) individuals (Figure 1B).
Ratio of vasoactive intestinal peptide and chymase 
or tryptase
We have previously shown that Chagas patients 
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(indeterminate and cardiac) had lower levels of VIP 
compared to controls and that cardiac patients had lower 
levels of this peptide in relation to indeterminate patients20. 
Thus, we evaluated the ratio of VIP, chymase and tryptase 
considering that the unbalance between VIP production and 
VIP degradation might be a determining factor contributing 
to the lower levels of VIP in those patients.
It was observed that VIP/CMA median ratio was lower 
in indeterminate (0.35; p<0.0001) and cardiac (0.21 ng/mL; 
p<0.0001) patients when compared to non-infected 
(1.16 ng/mL) individuals (Figure 1C). VIP/CMA ratio 
was also different between indeterminate and cardiac 
groups (p = 0.0458) (Figure 1C). In relation to the VIP/
TPS median ratio, a statistically significant difference 
Figure 1 - Plasma levels of Vasoactive Intestinal Peptide (VIP) Chymase (CMA), Tryptase (TPS) and VIP/Chymase (CMA) or 
VIP/Tryptase (TPS) ratios in chagasic patients. A) Plasma levels of VIP in non-infected individuals (NI), indeterminate patients (I) 
and cardiac patients (C). Plasma levels of TPS in non-infected individuals (NI) indeterminate patients (I) and cardiac individuals 
(C); B) Plasma levels of CMA in non-infected individuals (NI), indeterminate patients (I) and cardiac patients (C); C) Plasma levels 
of TPS in non-infected individuals (NI) indeterminate patients (I) and cardiac individuals (C); D) VIP/CMA ratio in non-infected 
individuals (NI) indeterminate patients (I) and cardiac individuals (C); E) VIP/TPS ratio in non-infected individuals (NI) indeterminate 
patients (I) and cardiac individuals (C). Q1, Q3 and median values are shown. Significant differences between groups are indicated 
by connecting lines. Kruskal-Wallis test followed by Mann-Withney test (p<0.05) were used for comparisons.
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was observed between indeterminate (0.14; p = 0.027) 
and cardiac patients (0.15; p = 0.012) and non-infected 
(0.28 ng/mL) individuals (Figure 1D). VIP/TPS median 
ratio was not different in the indeterminate (0.14 ng/mL) 
individuals when compared to the cardiac (0.15 ng/mL) 
patients (Figure 1D). 
Correlation analysis between chymase and tryptase
Since the peptidases are interdependent, the absence 
or inactivity of one enzyme can alter levels and activity 
of others24. As CMA and TPS are able to degrade VIP, we 
performed a correlation analysis between the levels of both 
enzymes in each studied group in order to observe if their 
expressions are related. A square relation between chymase 
and tryptase was observed in non-infected individuals. 
Therefore, values of TPS close to 40 ng/mL are followed by 
a reduction of CMA and values of TPS higher than 40 ng/mL 
are followed by an increase of CMA values (R2 = 0.65) 
(Figure 2A). In indeterminate individuals, a correlation was 
not observed between CMA and TPS expression (r = –0.26; 
p = 0.31) (Figure 2B). Interestingly, a positive linear 
correlation was observed between CMA and TPS levels 
in the cardiac group (r = 0.8; p = 0.003), indicating that 
higher levels of chymase were related with higher tryptase 
levels in those individuals (Figure 2C). Correlation analyses 
between CMA and TPS versus VIP were performed, 
however, they did not present any statistical significances 
(data not shown).
Ratio of vasoactive intestinal peptide and IL-17
IL-17 plasma levels were evaluated in indeterminate 
chagasic patients (n = 10), chagasic cardiac patients (n = 10) 
and non-infected individuals (n = 14). In relation to IL-17 
plasma levels, it was observed that cardiac Chagas patients 
presented higher levels of this cytokine (140.1 pg/mL) 
than the indeterminate  pat ients  (22.9 pg/mL; 
p = 0.0047) and non-infected individuals (57.6 pg/mL; 
p =  0.056). The production of IL-17 was also lower 
in indeterminate patients when compared to healthy 
individuals (p = 0.043) (Figure 3A). In relation to 
Figure 2 - Correlation analysis between plasma levels of CMA and TPS in chagasic patients. A) Correlation analysis between CMA 
and TPS plasma levels in non-infected individuals; B) Correlation analysis between CMA and TPS plasma levels in the indeterminate 
group; C) Correlation analysis between CMA and TPS plasma levels in the cardiac group. Statistical analyses were performed 
by using the square regression coefficient of determination (R2) for the NI group and the Spearman correlation coefficient (r) for I 
and C groups.
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IL-17/VIP ratio, a higher ratio was observed in chagasic 
cardiac patients (43.31) when compared to indeterminate 
(3.6; p = 0.0056) and non-infected individuals (4.9; 
p = 0.0059) (Figure 3B). Correlation analyses between 
IL-17 versus VIP were performed; however, they did not 
present statistical significances (Figure 3C-3E).
DISCUSSION
VIP is a neuropeptide constituted by 28 amino acids 
and presents a wide body distribution. VIP exerts a role 
as a modulator of innate and adaptive immunity, being 
a potent anti-inflammatory agent. VIP receptors, VPAC1 
and VPAC2 are expressed by several immunocompetent 
cells. The engagement of VIP with its G protein-coupled 
receptors activates AMPc/PKA and, consequently, activates 
transcription factors25 especially those favoring the anti-
inflammatory pathways. A higher expression of VIP has 
been related to a better prognosis in different chronic 
diseases16-19. 
This work and previous studies showed that VIP 
plasma levels are higher in non-infected individuals when 
compared to chagasic patients of indeterminate and cardiac 
clinical forms20. One hypothesis to explain the decrease of 
VIP expression in chagasic patients could be an increased 
expression of enzymes with VIPase activity. Mast cells 
produce and secrete many peptidases, such as chymase and 
tryptase, which are able to degrade VIP. Tryptase cleaves 
VIP rapidly at two sites and chymase cleaves VIP primarily 
at a single site21. Differences in peptidase activity between 
tryptase and chymase suggest that the consequences of 
protease release could vary according to the mast cell 
protease phenotype and the location in various tissues and 
species21. 
Results of the present work indicate that the lower 
expression of VIP in chagasic patients might be related to 
a higher expression of chymase. In addition, VIP/chymase 
ratio was lower in chagasic patients when compared to 
uninfected individuals and, the same ratio was also lower in 
cardiac patients when compared to the indeterminate form. 
Both results corroborate the hypothesis that chymase might 
contribute to the observed decrease of VIP levels detected 
in chagasic patients.
Tryptase expression was not significantly different 
amongst the groups analyzed. Correlation analyses between 
chymase and tryptase were performed. An equilibrium 
between the expressions of both enzymes was observed 
for non-infected individuals. In indeterminate patients, 
chymase/tryptase equilibrium expression seems to be lost. 
In chagasic cardiac patients, the higher the expression 
Figure 3 - Analyses of plasma IL-17, IL-17/VIP ratio and IL-17/VIP correlation in chagasic patients. A) IL-17 plasma levels of non-
infected (NI), indeterminate patients (I) and cardiac individuals (C); B) Plasma IL-17/VIP ratio of non-infected (NI), indeterminate 
patients (I) and cardiac individuals (C); C) Correlation analysis between IL-17 and VIP plasma levels in non-infected individuals; D) 
Correlation analysis between IL-17 and VIP plasma levels in the indeterminate group; E) Correlation analysis between IL-17 and 
VIP plasma levels in the cardiac group. Q1, Q3 and median values are shown. Significant differences between groups are indicated 
by connecting lines. Kruskal-Wallis test followed by Mann-Withney test (p<0.05) were used for comparisons. Correlation analyses 
were performed by using the Spearman correlation coefficient (r). 
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of chymase, the greater the expression of tryptase. It is 
known that peptidases might influence the expression 
levels and activity of others24, thus it is likely that the 
combined action of both enzymes may result in a decrease 
of VIP levels observed in cardiac patients. Moreover, 
these enzymes have a role in the inflammatory process, 
influencing leukocytes chemotaxis, lymphocytes activation, 
expression and release of proinflammatory chemokynes 
and cytokynes, leading to immunoregulatory disorders26-28. 
Altogether, chymase and tryptase may be related to cardiac 
damage in chagasic cardiac disease not only by decreasing 
VIP levels, but also by contributing to the exacerbation 
of inflammatory responses in cardiac patients. On the 
other hand, indeterminate individuals, despite presenting 
higher chymase levels and reduction of VIP/chymase 
ratio when compared to non-infected individuals, did not 
show a positive correlation between chymase and tryptase 
expression, which may indicate that in asymptomatic 
chagasic individuals, the enzymes do not present additive 
effects. This may be an important mechanism to maintain 
immune modulation, avoiding the occurrence of tissue 
damage in these patients. There are few studies evaluating 
the expression of VIP and its degrading proteases in cardiac 
Chagas disease. In the digestive form of Chagas disease, 
a higher expression of tryptase was found in patients 
presenting megaesophagus when compared to individuals 
without it or uninfected ones, suggesting that tryptase 
could participate in the megaesophagus development in 
infected individuals. The pro-inflammatory effects of 
this enzyme and its role in VIP degradation may be part 
of the mechanisms associated with the development of 
these severe digestive alterations29,30. Differences between 
those studies may rely on several characteristics such as: 
clinical forms; clinical characterization of patients; type 
of samples used; genetic and immune characteristics of 
patients and genetic variability of the parasite. Despite all 
these variables, all studies are valid and non-exclusive and 
show a clear correlation between lower VIP expression and 
disease severity. 
An in situ study evaluated the expression of chymase and 
tryptase by mast cells of individuals presenting digestive 
forms of Chagas disease. A higher concentration of mast 
cells reactive to tryptase was observed in Chagas individuals 
presenting megaesophagus or not when compared to non-
infected individuals. In relation to chymase expression 
by mast cells, a higher expression was observed only in 
infected individuals without megaesophagus30. Our results 
showed a higher expression of chymase in cardiac and 
indeterminate Chagas disease patients when compared 
to non-infected individuals. Moreover, we observed no 
differences of tryptase expression among the analyzed 
groups. It is possible that in digestive forms, tryptase is 
responsible for VIP degradation. Interestingly, chymase is 
involved in the development of cardiovascular diseases in 
animal models31.
In humans, a positive correlation between the collagen 
expression and chymase expressing mast cells was observed 
in the myocardium of chagasic patients suggesting that 
chymase may also be associated with fibrosis in cardiac 
Chagas disease32. It is possible that chymase expression 
in cardiac forms of Chagas disease, might be related 
to the aggravation of the cardiac disease, possibly by 
its VIPase, proinflammatory, vascular and fibrosing 
effects. Additionally, the tryptase expression seems to be 
coordinated with the chymase one, in cardiac patients, who 
might potentiate the chymase function.
Lower VIP levels have been related to worse prognosis, 
not only in Chagas disease20 but also in other chronic 
diseases. A study evaluated serum levels of VIP during 
the follow-up of an early arthritis (EA) cohort33. Patients 
fulfilling the criteria for rheumatoid arthritis (RA) 
presented the lowest values of VIP although no significant 
differences were observed in comparison with healthy 
donors. In addition, the disease activity was inversely 
correlated with VIP levels. After a two-year follow-up, 
patients with low baseline levels of VIP displayed higher 
disease activity. Another study analyzed the correlation 
between serum levels of VIP and disease activity/severity 
in patients with early chronic inflammatory back pain 
associated with Spondyloarthritis (SpA). Lower levels 
of VIP were significantly associated with a higher Bath 
Ankylosing Spondylitis Disease Activity Index (BASFI) 
score, presence of bone edema in magnetic resonance 
imaging (MRI) scans and lower hemoglobin levels. Results 
indicated that patients with low serum VIP levels had 
worse 2-year disease outcome34. Another study evaluating 
VIP levels in patients with osteoarthritic knee (OA), 
observed that OA patients had lower VIP concentrations 
in synovial fluid and articular cartilage. Moreover, the 
synovial fluid and articular cartilage lower levels of 
VIP were negatively correlated with disease severity35. 
All these studies indicate that lower VIP levels are 
related to a poor prognosis of the diseases and highlight 
the possibility of using VIP levels measurements as a 
prognostic biomarker.
The present work also evaluated if VIP expression may 
have some impact on IL-17 plasma expression since a 
decrease of Th1 and Th17 profiles is one of the VIP effects36. 
Th17 cells may present a pathogenic or non-pathogenic 
phenotype according to their cytokine secretion profile 
and VIP reduces the pathogenic profile of Th17-polarized 
cells13,37,38. 
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Some studies have been developed focusing on Th17 
population and/or IL-17 expression in cardiovascular 
diseases. An increase of peripheral Th17 cells and Th17 
related cytokines was observed in patients presenting dilated 
cardiomyopathy38,39. In Chagas disease, a recent study has 
analyzed the frequency of CD4+ CD25+FoxP3+ cells, classic 
Th17 cells, alternative Th17 cells and IL-17+ B cells from 
peripheral blood of chronic cardiac patients after in vitro 
stimulation with T. cruzi antigen. The results showed that 
CD4+ CD25+ FoxP3+, CD4+ CD25high FoxP3+, CD4+ IL-17+ 
IFN-γ- and CD4+ IL-17+ IFN-γ+ cells are more frequent in 
patients with severe cardiac disease and these findings 
correlate with the worsening of global cardiac function. 
IL-17 expression by Th17 cells and B cells correlated with 
disease progression. These results suggest that the clinical 
progression of Chagas cardiomyopathy involves worsening 
of inflammation and impairment of immunoregulatory 
mechanisms with IL-17 participation40.
Regarding Chagas disease, a report on the role of IL-17 
and regulatory T cells in human Chagas disease showed 
higher percentages of CD4+IL-17+ cells in PBMC cultured 
from patients with or without mild cardiomyopathy, 
in comparison with patients presenting moderate or 
severe cardiomyopathy41. The study also showed that 
CD4+CD25+ T cells from patients with mild or without 
cardiomyopathy presented higher suppressive activity 
than those with moderate and severe cardiomyopathy. The 
authors concluded that deficient regulatory T cell activity 
and low frequency of IL-17-producing T cells correlate 
with the extent of cardiomyopathy in human Chagas 
disease41. Another study investigated the intracellular IL-
17 expression and its association with the indeterminate or 
cardiac clinical forms of Chagas disease and with patients’ 
cardiac function14. Their results demonstrated that cardiac 
patients presented a lower intensity of IL-17 expression by 
total lymphocytes and a lower frequency of circulating T 
helper 17 cells. Another study evaluating the expression of 
IL-17 in plasma samples of Chagas patients15 observed that 
a significant frequency of indeterminate patients presented 
high levels of IL-17A, whereas most of the cardiac patients 
expressed low plasma levels of this cytokine. Thus, the 
authors have shown that low and high IL-17A producers 
were observed in both groups. A recent study investigated 
the associations between genetic polymorphisms of IL17A 
G197A and IL17F T7488C with Chagas disease (CD) 
and/or the severity of left ventricular systolic dysfunction 
(LVSD). The analysis according to the gender showed 
that the A/A genotype of IL17A was more frequent in 
female patients with LVSD and mild to moderate LVSD, 
and also in male patients with LVSD. The frequency of 
IL17F T/C genotype was higher in male patients with CCC 
and severe LVSD and in females with mild to moderate 
LVSD. The mutant allele A of IL17A was associated with 
a higher production of IL-17 and it is known that IL-17F 
activity is similar to IL-17A. Based on these findings, it is 
possible to infer that the higher production of IL-17 could 
contribute to tissue damage and might be related to the 
development and progression of CCC42. In our study, we 
observed a higher plasma expression of IL-17A in cardiac 
patients when compared to indeterminate ones. However, 
our study presented a restrict sample size in relation to 
the cited study and, it seems that most of our patients 
belonged to the high IL-17A producers group. In relation 
to IL-17/VIP ratio, we observed a higher ratio in chagasic 
cardiac patients when compared with indeterminate and 
non-infected individuals. It is a direct effect of the elevated 
expression of IL-17 in the cardiac group analyzed by us 
and the lower expression of VIP in those patients. This 
result may indicate a lack of modulation of Th17 cells 
due to decreased VIP expression, which may cause these 
cells to develop a pathogenic profile that, in this cardiac 
group, may contribute to heart damage. Studies to define 
the profile of Th17 cells in clinical forms of Chagas disease 
are necessary.
In summary, our results suggest that the ratio between 
production/degradation of VIP is compromised in 
chagasic patients, and the unbalanced levels of VIP may 
have implications on IL-17 expression. Future studies 
are necessary to point out how VIP and VIPase enzymes 
influence the immune system response in chronic 
inflammatory diseases, which could allow the proposition of 
new treatment strategies and/or new therapeutic associations 
aiming the improvement of patients’ management. 
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